Track The Joint Corp. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

The Joint Corp. JYNT · Stock Open The Joint Corp. in new tab

6.97 USD
P/E
31.55
EPS
0.22
P/B
7.49
ROE
18.55
Beta
1.16
Target Price
9.00 USD
The Joint Corp. logo

The Joint Corp.

🧾 Earnings Recap – Q2 2026

The Joint Corp’s Q2 earnings produced little market reaction, reflecting a largely in-line performance without clear surprises on either upside or downside.

  • Revenue grew 14% year-over-year to $15.2 million, driven by continued refranchising progress and franchise-related income.
  • Adjusted EBITDA improved by $1.4 million to $1.5 million, reflecting operating leverage as the company shifts to a capital-light franchisor model.
  • Consolidated net income increased to $653,000 from $93,000 in Q2 2025, supported by disciplined capital allocation and improved patient retention.
  • Cash flow from operations grew 152% year-over-year to $2.2 million, resulting in $1.9 million free cash flow, benefiting from refranchising and cost control.
  • Management highlighted successful refranchising transactions reducing company-owned clinics to just three, positioning for franchise growth but did not provide new organic growth metrics or updated guidance.
📅
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
P/E31.55
EPS0.22
Book Value0.93
Price to Book7.49
Debt/Equity15.93
% Insiders18.561%
Growth
Revenue Growth0.01%
Earnings Growth6.53%
Estimates
Forward P/E11.02
Forward EPS0.63
Target Mean Price9.00

DCF valuation

Model fair value for The Joint Corp. (JYNT)
Result
Sign in to run the valuation for JYNT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Buy · mean target 9.00 USD (low 8.00, high 10.00) · as of 15 Nov 2026
Low 8.00
Mean 9.00
High 10.00
Price 6.97
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

The Joint Corp. Logo The Joint Corp. Analysis (JYNT)

United States Health Care Official Website Stock

Is The Joint Corp. a good investment? The Joint Corp. (JYNT) is currently trading at 6.97 USD. Market analysts have a consensus price target of 9.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 31.55. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: The Joint Corp. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is 0.63.

Investor FAQ

Does The Joint Corp. pay a dividend?

No, it does not currently pay a dividend.

What asset class is The Joint Corp.?

The Joint Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of 0.22.

Company Profile

The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. It operates through a network of franchised clinics, offering routine and affordable chiropractic adjustments using a private pay, non-insurance, cash-based model. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Exchange Ticker
NMS (United States) JYNT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion